Literature DB >> 18180382

BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia.

Kechen Ban1, Yin Gao, Hesham M Amin, Adrienne Howard, Claudia Miller, Quan Lin, Xiaohong Leng, Mark Munsell, Menashe Bar-Eli, Ralph B Arlinghaus, Joya Chandra.   

Abstract

Chronic myelogenous leukemia (CML) invariably progresses to blast crisis, which represents the most proliferative phase of the disease. The BCR-ABL1 oncogene stimulates growth and survival pathways by phosphorylating numerous substrates, including various Src family members. Here we describe up-regulation, in contrast to activation, of the ubiquitously expressed Src kinase, Fyn, by BCR-ABL1. In a tissue microarray, Fyn expression was significantly increased in CML blast crisis compared with chronic phase. Cells overexpressing BCR-ABL1 in vitro and in vivo display an up-regulation of Fyn protein and mRNA. Knockdown of Fyn with shRNA slows leukemia cell growth, inhibits clonogenicity, and leads to increased sensitivity to imatinib, indicating that Fyn mediates CML cell proliferation. In severe combined immunodeficient (SCID) mice injected with Fyn shRNA-expressing cells, myeloid-derived cell numbers dropped by 50% and death from leukemia was delayed. Taken together, these results encourage the development of therapies targeting Fyn expression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18180382      PMCID: PMC2254539          DOI: 10.1182/blood-2007-05-091769

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells.

Authors:  Andrzej Ptasznik; Yuji Nakata; Anna Kalota; Stephen G Emerson; Alan M Gewirtz
Journal:  Nat Med       Date:  2004-10-24       Impact factor: 53.440

2.  Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression.

Authors:  K M Klucher; D V Lopez; G Q Daley
Journal:  Blood       Date:  1998-05-15       Impact factor: 22.113

3.  Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.

Authors:  M E Gorre; M Mohammed; K Ellwood; N Hsu; R Paquette; P N Rao; C L Sawyers
Journal:  Science       Date:  2001-06-21       Impact factor: 47.728

4.  Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.

Authors:  S Danhauser-Riedl; M Warmuth; B J Druker; B Emmerich; M Hallek
Journal:  Cancer Res       Date:  1996-08-01       Impact factor: 12.701

Review 5.  BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia.

Authors:  Sheila A Doggrell
Journal:  Expert Opin Investig Drugs       Date:  2005-01       Impact factor: 6.206

6.  Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias.

Authors:  Dejan Juric; Norman J Lacayo; Meghan C Ramsey; Janis Racevskis; Peter H Wiernik; Jacob M Rowe; Anthony H Goldstone; Peter J O'Dwyer; Elisabeth Paietta; Branimir I Sikic
Journal:  J Clin Oncol       Date:  2007-02-20       Impact factor: 44.544

Review 7.  Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation.

Authors:  Emil H Palacios; Arthur Weiss
Journal:  Oncogene       Date:  2004-10-18       Impact factor: 9.867

8.  Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.

Authors:  Yiguo Hu; Yuhua Liu; Shawn Pelletier; Elisabeth Buchdunger; Markus Warmuth; Doriano Fabbro; Michael Hallek; Richard A Van Etten; Shaoguang Li
Journal:  Nat Genet       Date:  2004-04-18       Impact factor: 38.330

9.  Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells.

Authors:  Joya Chandra; Jennifer Hackbarth; Son Le; David Loegering; Nancy Bone; Laura M Bruzek; Ven L Narayanan; Alex A Adjei; Neil E Kay; Ayalew Tefferi; Judith E Karp; Edward A Sausville; Scott H Kaufmann
Journal:  Blood       Date:  2003-08-14       Impact factor: 22.113

10.  BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

Authors:  Nicholas J Donato; Ji Yuan Wu; Jonathan Stapley; Gary Gallick; Hui Lin; Ralph Arlinghaus; Moshe Talpaz
Journal:  Blood       Date:  2003-01-15       Impact factor: 22.113

View more
  23 in total

1.  Inhibition of the NADPH oxidase regulates heme oxygenase 1 expression in chronic myeloid leukemia.

Authors:  Melissa M Singh; Mary E Irwin; Yin Gao; Kechen Ban; Ping Shi; Ralph B Arlinghaus; Hesham M Amin; Joya Chandra
Journal:  Cancer       Date:  2011-12-02       Impact factor: 6.860

2.  Fusion of the COL1A1 and FYN Genes in Epithelioid Osteoblastoma.

Authors:  Ioannis Panagopoulos; Ludmila Gorunova; Ingvild Lobmaier; Marius Lund-Iversen; Kristin Andersen; Arild Holth; Bodil Bjerkehagen; Sverre Heim
Journal:  Cancer Genomics Proteomics       Date:  2019 Sep-Oct       Impact factor: 4.069

3.  Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration.

Authors:  Vipin Yadav; Mitchell F Denning
Journal:  Mol Carcinog       Date:  2010-12-10       Impact factor: 4.784

4.  Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models.

Authors:  Noriko Doki; Jiro Kitaura; Tomoyuki Uchida; Daichi Inoue; Yuki Kagiyama; Katsuhiro Togami; Masamichi Isobe; Shinichi Ito; Akie Maehara; Kumi Izawa; Naoko Kato; Toshihiko Oki; Yuka Harada; Fumio Nakahara; Hironori Harada; Toshio Kitamura
Journal:  Int J Hematol       Date:  2011-12-22       Impact factor: 2.490

5.  Novel modeling of cancer cell signaling pathways enables systematic drug repositioning for distinct breast cancer metastases.

Authors:  Hong Zhao; Guangxu Jin; Kemi Cui; Ding Ren; Timothy Liu; Peikai Chen; Solomon Wong; Fuhai Li; Yubo Fan; Angel Rodriguez; Jenny Chang; Stephen T C Wong
Journal:  Cancer Res       Date:  2013-10-04       Impact factor: 12.701

Review 6.  Redox control of leukemia: from molecular mechanisms to therapeutic opportunities.

Authors:  Mary E Irwin; Nilsa Rivera-Del Valle; Joya Chandra
Journal:  Antioxid Redox Signal       Date:  2012-09-28       Impact factor: 8.401

Review 7.  Molecular biology of bcr-abl1-positive chronic myeloid leukemia.

Authors:  Alfonso Quintás-Cardama; Jorge Cortes
Journal:  Blood       Date:  2008-09-30       Impact factor: 22.113

8.  Oxidative stress promotes transcriptional up-regulation of Fyn in BCR-ABL1-expressing cells.

Authors:  Yin Gao; Adrienne Howard; Kechen Ban; Joya Chandra
Journal:  J Biol Chem       Date:  2009-01-08       Impact factor: 5.157

Review 9.  Recent advances in understanding chronic myeloid leukemia: where do we stand?

Authors:  Rahul Kumar; Daniela S Krause
Journal:  Fac Rev       Date:  2021-04-01

10.  Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells.

Authors:  Ping Shi; Joya Chandra; Xiaoping Sun; Mate Gergely; Jorge E Cortes; Guillermo Garcia-Manero; Ralph B Arlinghaus; Raymond Lai; Hesham M Amin
Journal:  J Cell Mol Med       Date:  2009-06-05       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.